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Abstract
Background: Markers of crypt cell proliferation are frequently employed in studies of the impact
of genetic and exogenous factors on human colonic physiology. Human studies often rely on the
assessment of tissue acquired at endoscopy. Modulation of cell proliferation by bowel preparation
with oral laxatives may confound the findings of such studies, but there is little data on the impact
of commonly used bowel preparations on markers of cell proliferation.
Methods: Crypt length, crypt cellularity and crypt cell proliferation were assessed in biopsies
acquired after preparation with either Klean-Prep or Picolax. Crypt cell proliferation was assessed
by whole-mount mitotic figure count, and by two different immunohistochemical (IHC) labelling
methods (Ki-67 and pHH3). Subsequent biopsies were obtained from the same patients without
bowel preparation and similarly assessed. Parameters were compared between groups using
analysis of variance and paired t-tests.
Results: There were significant differences in labelling indices (LI) between biopsies taken after
Klean-prep and those taken after Picolax preparation, for both Ki67 (p = 0.019) and pHH3 (p =
0.017). A similar trend was seen for whole-mount mitotic figure counts. Suppression or elevation
of proliferation parameters by bowel preparation may mask any effect due to an intervention or
disease.
Conclusion: Commonly used bowel preparations may have significant and different effects on
crypt cell proliferation. This should be taken into account when designing studies and when
considering the findings of existing studies.
Background
Oral laxatives are routinely used to cleanse the colon prior
to colonoscopy, to permit clear visualisation of the
colonic mucosa and minimise the risk of infection.
Hyperosmotic preparations such as sodium phosphate
(NaP) and Picolax® actively draw water into the bowel
lumen, increasing stool bulk and stimulating gut motil-
ity[1]. The effect is lavage with rapid transit and evacua-
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tion of bowel contents. The fluid and electrolyte
imbalance that may occur with preparations of this type
precludes their use in patients with renal or congestive
heart failure, but they are otherwise well tolerated[2].
Klean-Prep® is principally a lavage solution with some
osmotic activity, the large ingestion volume being
retained within the colon by polyethelene glycol (PEG),
itself relatively inert and poorly absorbed. Although the
risk of significant fluid or electrolytes shifts is reduced
with PEG based preparations[3], the large ingestion vol-
ume can be associated with poor patient compliance[4].
Ideally, a bowel preparation agent should have minimal
impact on the colonic mucosa. However, endoscopic and
histological abnormalities have been reported, particu-
larly with NaP, and include inflammation, haemorrhage,
focal active colitis (FAC), erosion of the surface epithe-
lium and apthoid ulceration [5-7]. One study reported
apthoid lesions in 24.5% of patients prepared with NaP,
compared to only 2.3% of patients prepared with PEG
and concluded that NaP should not be used to prepare
patients with suspected inflammatory bowel disease[8].
Another study attributing FAC and aphthoid ulcers to NaP
found no lesions in a subset of patients subsequently re-
examined without preparation[9]. Sodium picosulfate,
the active constituent of Picolax, has been shown to
increase the expression of acidic mucin and cytokeratin
AE1 in rat colonocytes[10]. The effects of PEG on the mor-
phology of the colonic mucosa are less clear. No signifi-
cant changes were attributed to PEG in two studies of
human and rat colon[6,7]. However, subtle structural
changes including mucin depletion, epithelial cell loss
and inflammatory cell infiltration of the mucosa have
been reported elsewhere[5].
Cell proliferation is a commonly used end-point in stud-
ies of the effects of exogenous and genetic factors on
colonic mucosal function and cancer risk. However, data
on the impact of bowel preparation agents on cell prolif-
eration is sparse. A 136% increase in colonocyte Ki-67
labelling index has been reported in patients prepared
with NaP, when compared to the same patients, unpre-
pared[9]. Sodium picosulfate was found in an animal
study to have no effect on colonocyte proliferation[11],
whilst another detected increased proliferation in
response to bisocodyl and sennosides, laxatives with a
similar action[12].
To date, there are no published studies examining or com-
paring the direct effects of sodium picosulfate and PEG on
colonocyte proliferation. This study aims to compare the
effects of these two commonly used bowel preparative
agents on immunohistochemical and whole-mount
derived indices of cell proliferation.
Methods
Ethical approval and patient groups
Patients attending endoscopy clinics at the Northern Gen-
eral Hospital, Sheffield for an initial colonoscopy were
recruited to the study. Patients were all male, over 40 and
had normal bowel health. Smokers and diabetics were
excluded. Patients prepared for endoscopy with Klean-
Prep (n = 4) or Picolax (n = 3) were invited to return four
weeks later for sigmoidoscopy without bowel prepara-
tion. Two biopsies were taken at the recto-sigmoid junc-
tion. This study was approved by the North Sheffield
Research Ethics Committee (Reference number: 06/
Q2308/93). Informed consent was obtained from all
patients.
Measurement of crypt cell proliferation
The range of markers currently utilised for the assessment
of colonocyte proliferation is wide, and may in part
account for the variability seen between studies. In this
study we employed two recognised immunohistochemi-
cal markers of cell proliferation, Ki-67 and pHH3. Ki-67 is
expressed throughout the cell cycle, whilst pHH3 (phos-
phorylated histone H3) is detectable in increasing quan-
tity during the progression from from interphase to
prophase. This correlates with a progression from granular
to diffuse immunohistochemical staining patterns[13].
Counts for both staining patterns were recorded. Where
possible, an additional biopsy from each site was taken
for whole-crypt mitotic count, assessed using the micro-
dissection method described by Goodlad, et. al[14].
Immunohistochemical Analyses
Biopsies were fixed for 24 hours in formalin before paraf-
fin embedding and cutting of serial 4-micron sections at
40-micron intervals. Endogenous peroxidise activity was
blocked with 2% hydrogen peroxide. Heat-induced eip-
tope retrieval (HIER) was performed using a sodium cit-
rate buffer (pH 6.0) for Ki-67 and EDTA (pH 8.0) for
pHH3. Non-specific immunoglobulin binding sites were
blocked with normal horse serum. Slides were incubated
for 1 hour with primary antibodies to Ki-67 (Vector Labo-
ratories VP-K 452) and pHH3 (Upstate 06–570) at 1:100
and 1:200, respectively. Staining was visualised with the
Vectastain Universal Elite kit and DAB peroxidise sub-
strate (Vector Laboratories). Sections were counter-
stained with Gill's haematoxylin.
A maximum of 10 well-orientated hemi-crypts per biopsy,
showing the entire length of the crypt wall from the base
abutting the muscularis mucosa through to the junction
with the surface epithelium, were included. Images were
captured at 20× magnification with a Nikon D5-M camera
at 2560 × 1920 resolution, stored without compression
and analysed using Nikon NIS-Elements D (v 2.30) soft-
ware. All cell counts and measurements were made by oneBMC Gastroenterology 2008, 8:54 http://www.biomedcentral.com/1471-230X/8/54
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observer blind to the status of the biopsy. A subset of
scores was confirmed by a second independent observer.
The number of cells showing positive nuclear staining for
each antigen was recorded as a fraction of the total cell
count per hemi-crypt (labelling index:LI). For pHH3, the
LIs for granular and diffuse staining were recorded sepa-
rately. Crypt lengths for up to five crypts per biopsy were
determined.
Whole mount analysis
Whole biopsies were fixed in Carnoy's fluid, then stored
in 70% ethanol. Rehydration through 50% and 25% alco-
hols and PBS was followed by hydrolysis in 5 M NaOH at
room temperature. After staining with Schiff's reagent for
90 minutes, the biopsies were transferred to 45% acetic
acid for dissection. Small groups of crypts were isolated
from surrounding tissue under a dissecting microscope,
then transferred to slides and squashed with thumb pres-
sure under a cover-slip with aqueous mountant. Mitoses
were counted at ×40 in up to ten whole crypts per biopsy,
through the full crypt depth. Nuclei in all phases of mito-
sis were counted and expressed as the number of mitoses
per crypt.
Statistics
Statistical analysis was carried out with SPSS (version
11.0). The distribution of values for each parameter was
tested for normality using the Kolmorogov-Smirnov test.
Indices for paired biopsies (i.e those from the same
patient, with and without preparation) were compared
using the paired Student t-test. One-way ANOVA was used
to test for the equality of the means for each parameter
between each group (no preparation, Klean-Prep and
Picolax), and the unpaired t-test was used to test for differ-
ences between biopsies taken after Klean-prep and those
taken after Picolax.
Results and discussion
Proliferation indices
Immunohistochemical methods for the assessment of cell
proliferation in small biopsies suffer from a number of
potential disadvantages. Firstly, it can be difficult to
obtain high yields of assessable crypts in histological sec-
tions. Secondly, there is concern over the impact of the so
called "denominator effect" on the LI. Counting mitotic
figures in whole-mount preparations avoids these issues,
but does suffer the disadvantage that a second biopsy
must be obtained if conventional histolological examina-
tion (or additional immunohistochemical staining, e.g.
for apoptosis) is required. We compared the statistical
reliability of both approaches using the Cronbach's alpha
statistic -a measure of between and within-case variability,
ranging from 0 to 1 with increasing reliability. The scores
were 0.9476 and 0.9164 for Ki-67 and whole mount
mitotic counts, respectively, indicating that robust meas-
urements can be obtained without exhaustive sampling of
crypts. Moreover, scores from both methods correlated
well (Pearson correlation coefficient 0.655, p = 0.008).
There is also concern that individual antibody targets may
not display expression that is truly restricted to proliferat-
ing cells, and therefore give potentially spurious results. It
is reassuring that the immunohistochemical markers used
in this study both showed similar results.
Two immunohistochemical markers of cell proliferation,
Ki-67 and pHH3, were measured. Colonocyte Ki-67 LI
decreased after preparation with Klean-Prep, when com-
pared with unprepared bowel from the same patients (Fig-
ure 1A). Despite the consistent change, significance was
not achieved (p = 0.117, paired t-test). A decrease was also
seen in the number of whole-crypt mitoses with Klean-
Prep (Figure 1B). Again, the trend was consistent but sig-
nificance was not achieved (p = 0.118). Klean-Prep had no
apparent effect on pHH3 diffuse or granular staining,
when compared to that seen in the same patients without
preparation (p = 0.519 and p = 0.562, respectively, data
not shown).
Picolax had an opposing effect on colonocyte prolifera-
tion. Ki-67 LI increased after preparation with Picolax,
although this effect was not significant (p = 0.2778, Figure
2). Similarly, increased diffuse and granular pHH3 stain-
ing was observed with Picolax and reached significance in
the granular fraction (p = 0.049, p = 0.269 for positive
staining, data not shown). Paired samples from only one
patient were available for whole crypt staining; the mean
number of mitoses per crypt for this patient were 11.4 and
5.0 for Picolax and unprepared biopsies, respectively.
While obvious and consistent trends are seen in the above
analysis, treating the samples as paired for statistical pur-
poses is undermined by the small numbers (n = 4 for
Klean-Prep, n = 3 for Picolax) and the unavailability of
paired biopsies for all markers tested. All data, paired or
otherwise, was therefore redistributed into treatment
groups and subjected to analysis of variance (ANOVA)
testing. One-way ANOVA revealed significant differences
between groups (Ki-67: p = 0.035, mitoses: p = 0.045),
demonstrating, as for the paired analysis, a decrease in
proliferation with Klean-Prep, and an increase with Pico-
lax, when compared to unprepared bowel (Figure 3).
Scoring differentially for granular and positive pHH3
staining showed a similar pattern of response to bowel
preparation (data not shown), but statistical significance
was reached when the data sets were combined to give a
total LI (p = 0.038, Figure 4). Post-hoc analysis revealed a
significant difference between Klean-Prep and Picolax on
Ki-67 and total pHH3 LI (p = 0.019 and 0.017, respec-
tively).BMC Gastroenterology 2008, 8:54 http://www.biomedcentral.com/1471-230X/8/54
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This observation may be relevant to the interpretation of
proliferation data in several recently published studies. In
one study demonstrating no significant difference in Ki-
67 or whole crypt mitoses between patients with Heredi-
tary non-polyposis colorectal cancer and normal subjects,
the authors concluded that crypt cell proliferation is not a
suitable discriminative marker for this disease[15]. All
patients had been administered Picolax and, as in our
study, had Ki-67 LIs in the range 0.3 to 0.4[16]. A study on
the effect of pre-biotic carbohydrates similarly showed no
difference in Ki-67 LI between subjects and controls,
reporting indices between 0.3 and 0.4. Again, all subjects
received Picolax. Our evidence suggests that any marginal
change in LI in response to disease or intervention in these
studies may have been masked by the proliferative effects
of Picolax. Equally, data from studies based on subjects
prepared with PEG should be interpreted cautiously. No
association was found between the PCNA proliferative
index (PI) and the likelihood of developing adenoma in
one prospective study; the majority of these patients were
prepared with PEG[17]. It is possible that PEG suppressed
colonocyte proliferation in a group of patients that might
be expected to have a higher than normal PI.
Crypt length and cellularity
No significant differences were seen by t-test analysis
between pairs for either Klean-Prep or Picolax (p = 0.766
and 0.183, respectively), or between groups by one-way
ANOVA (p = 0.437). Similarly, there was no significant
difference in crypt length between pairs (p = 0.209 for
Klean-prep, p = 0.827 for Picolax), or between groups by
one-way ANOVA (p = 0.0786) (data not shown). The cel-
lular homeostasis observed despite increased prolifera-
tion could be attributed to two factors. Firstly, the interval
between bowel preparation and biopsy (typically 12
hours) may have been insufficient for any cells entering
cell division to complete the cycle. Secondly, the observed
homeostasis may be attributable to increased apoptosis.
Our assessment of apoptotic indices recorded very low
rates of background apoptosis in all samples, and showed
no alteration in response to bowel preparation (data not
shown).
Paired t-test analysis of Ki-67 LI in patients prepared with  Picolax Figure 2
Paired t-test analysis of Ki-67 LI in patients prepared 
with Picolax. A trend towards elevation of Ki-67 LI is seen 
with Picolax compared to unprepared bowel from the same 
patients.
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Paired t-test analyses of proliferative indices in patients prepared with Klean-Prep Figure 1
Paired t-test analyses of proliferative indices in patients prepared with Klean-Prep. A consistent trend towards 
suppression of both Ki-67 (A) and mitoses (B) is seen with Klean-Prep compared to unprepared bowel from the same patients.
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Limitations of study
A randomisation bias on clinical grounds cannot be ruled
out in the allocation of patients to Klean-Prep or Picolax
preparation; this, along with the small sample size, may in
part account for the lack of statistical significance seen
between prepared patients and unprepared controls. Sim-
ilarly, whilst patients prepared with Klean-Prep or Picolax
fasted prior to colonoscopy, control patients did not, and
potential confounding influences of luminal nutrition
and luminal workload on proliferation indices should be
noted. However, our analyses, and the central finding of
this study, show an opposing direction of change between
Klean-Prep and Picolax that is consistent for all prolifera-
tion measures, and cannot be a feature of starvation.
Although the small number of cases and the single sam-
pling site inevitably means that the results should be
interpreted with caution, this pilot study has informed
our choice of procedural homogeneity for a separate,
larger study requiring repeat endoscopies.
Conclusion
This study demonstrates that Picolax and Klean-Prep have
significantly different effects on crypt cell proliferation.
Suppression or elevation of proliferation parameters by
bowel preparation may mask any effect due to an inter-
vention or disease.
These data underscore the importance of ensuring that all
patients participating in studies in which crypt prolifera-
tion is an outcome measure are treated with identical
bowel preparation. Bowel preparations used in such stud-
ies should be reported, and the data interpreted with cau-
tion.
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ANOVA of Ki-67 and mitotic figures in unprepared and prepared bowel Figure 3
ANOVA of Ki-67 and mitotic figures in unprepared and prepared bowel. Significant differences were seen between 
all groups (p = 0.035 and p = 0.045 for Ki-67 (A) and mitotic figures (B), respectively), with a marked difference in Ki-67 
between Klean-Prep and Picolax (p = 0.019). Crypts with a low Ki-67 LI, from a bowel prepared with Klean-Prep, and with a 
high LI, from a Picolax prepared bowel, are shown in B and C, respectively.
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